Anne B. Warwick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anne B. Warwick has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Allen Melemed
Eli Lilly and Company, Indianapolis, Indiana
1 shared publication- Conrad Vincent Fernandez
IWK Health Centre, Dalhousie University, Halifax, NS, Canada
1 shared publication - Elizabeth A. Mullen
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA
1 shared publication - Elizabeth J. Perlman
Department of Pathology and Laboratory Medicine, The Ann and Robert H. Lurie Children's Hospital of Chicago Northwestern University Chicago IL USA
1 shared publication - Geetika Khanna
Children’s Healthcare of Atlanta, Atlanta, GA
1 shared publication - James I. Geller
Peckham Center for Cancer and Blood Disorders, Rady Children's Hospital, San Diego, CA
1 shared publication
Latest Publications
- 1 September 2019
- Published by Elsevier in European Journal of Cancer
- Vol. 118, 58-66
Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study
- 1 September 2019
- Published by Elsevier in European Journal of Cancer
- Vol. 118, 58-66
Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study
- 28 June 2012
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 60 (2) , 237-241
Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: A Children's Oncology Group study
Background: Pemetrexed is a multi‐targeted antifolate that inhibits key enzymes involved in nucleotide biosynthesis. We performed a phase 2 trial of pemetrexed in children with refractory or recurrent solid tumors, including CNS tumors, to estimate the response rate and further define its toxicity profile.Procedure: Pemetrexed, at a dose of 1910 mg/m2, was administered as a 10‐minute intravenous infusion every 21 days. Patients also received vitamin B12, daily multivitamin supplementation, and dexamethasone. A two‐stage design (10 + 10) was employed in each of the following disease strata: osteosarcoma, Ewing sarcoma/peripheral primitive neuroectodermal tumor (PNET), rhabdomyosarcoma, neuroblastoma, ependymoma, medulloblastoma/supratentorial PNET, and non‐brainstem high‐grade glioma.Results: Seventy‐two eligible subjects (39 males) were enrolled. Median age was 11 years (range 3–23). Sixty‐eight were evaluable for response. The median number of cycles administered was 2 (range 1–13). No complete or partial responses were observed. Stable disease, for a median of 5 (range 4–13) cycles, was observed in five patients (ependymoma, Ewing sarcoma, medulloblastoma, neuroblastoma, osteosarcoma; n = 1 each). Neutropenia (44%), anemia (35%), and elevated alanine transaminase (35%) attributable to pemetrexed were the most commonly recurring toxicities observed in patients receiving multiple cycles. Other toxicities attributed to pemetrexed occurring in ≥10% of cycles included thrombocytopenia (30%), fatigue (18%), nausea (14), hyperglycemia (13%), rash (11%), vomiting (13%), and hypophosphatemia (11%).Conclusions: Pemetrexed, administered as an intravenous infusion every 21 days, was tolerable in children and adolescents with refractory solid tumors, including CNS tumors, but did not show evidence of objective anti‐tumor activity in the childhood tumors studied. Pediatr Blood Cancer 2013;60:237–241.
- 28 June 2012
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 60 (2) , 237-241
Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: A Children's Oncology Group study
Background: Pemetrexed is a multi‐targeted antifolate that inhibits key enzymes involved in nucleotide biosynthesis. We performed a phase 2 trial of pemetrexed in children with refractory or recurrent solid tumors, including CNS tumors, to estimate the response rate and further define its toxicity profile.Procedure: Pemetrexed, at a dose of 1910 mg/m2, was administered as a 10‐minute intravenous infusion every 21 days. Patients also received vitamin B12, daily multivitamin supplementation, and dexamethasone. A two‐stage design (10 + 10) was employed in each of the following disease strata: osteosarcoma, Ewing sarcoma/peripheral primitive neuroectodermal tumor (PNET), rhabdomyosarcoma, neuroblastoma, ependymoma, medulloblastoma/supratentorial PNET, and non‐brainstem high‐grade glioma.Results: Seventy‐two eligible subjects (39 males) were enrolled. Median age was 11 years (range 3–23). Sixty‐eight were evaluable for response. The median number of cycles administered was 2 (range 1–13). No complete or partial responses were observed. Stable disease, for a median of 5 (range 4–13) cycles, was observed in five patients (ependymoma, Ewing sarcoma, medulloblastoma, neuroblastoma, osteosarcoma; n = 1 each). Neutropenia (44%), anemia (35%), and elevated alanine transaminase (35%) attributable to pemetrexed were the most commonly recurring toxicities observed in patients receiving multiple cycles. Other toxicities attributed to pemetrexed occurring in ≥10% of cycles included thrombocytopenia (30%), fatigue (18%), nausea (14), hyperglycemia (13%), rash (11%), vomiting (13%), and hypophosphatemia (11%).Conclusions: Pemetrexed, administered as an intravenous infusion every 21 days, was tolerable in children and adolescents with refractory solid tumors, including CNS tumors, but did not show evidence of objective anti‐tumor activity in the childhood tumors studied. Pediatr Blood Cancer 2013;60:237–241.